Brainstorm Cell Ther (BCLI) 0.2701 $BCLI BrainStorm and

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Brainstorm Cell Ther (BCLI) 0.2701 $BCLI

BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical Trial
Marketwire - Tue Mar 25, 5:01AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Massachusetts General Hospital (MGH) in Boston, MA to conduct a Phase II clinical trial of NurOwn(TM) in amyotrophic lateral sclerosis (ALS), pending FDA and Institutional Review Board approvals. The other two clinical sites slated for the multi-center trial are the University of Massachusetts Memorial (UMass) Hospital and Mayo Clinic. Dana Farber Cancer Institute's Connell and O'Reilly Cell Manipulation Core Facility will manufacture the NurOwn cells for MGH and UMass Hospital.

BrainStorm Granted Key US Patent for Its Autologous Stem Cell Technology
Marketwire - Mon Mar 24, 5:29AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the U.S. Patent and Trademark Office has granted the company a key patent for its autologous stem cell technology. The patent (No. 8,663,987) covers BrainStorm's proprietary stem cells induced to secrete elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases.

Amber Road Makes Market Debut; Tranzbyte Corporation Signs LOI with Abattis
ACCESSWIRE - Sun Mar 23, 11:30PM CDT
Amber Road, Inc. (NYSE: AMBR) - For an in-depth report on Amber Road, Inc. follow: www.BullTrends.com/stockquote/AMBR

BrainStorm to Present Latest Company Developments at Regen Med Investor Day March 26 in New York
Marketwire - Tue Mar 18, 8:45AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Mr. Chen Schor, Executive Board Member, will present the company's latest developments at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City.

BrainStorm Cell Therapeutics awarded USD600,000 non-dilutive grant
M2 - Wed Feb 26, 5:59AM CST
Stem cell company BrainStorm Cell Therapeutics (OTCQB:BCLI), based in the US and Israel, disclosed on Tuesday the receipt of an additional USD600,000 non-dilutive grant from Israel's Office of the Chief Scientist (OCS) for the year 2014.

BrainStorm Receives Additional $600,000 Non-Dilutive Grant From Israel's Office of the Chief Scientist
Marketwire - Tue Feb 25, 8:15AM CST
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that BrainStorm Cell Therapeutics Ltd. was awarded an additional non-dilutive grant from Israel's Office of the Chief Scientist (OCS) for the year 2014 in the amount of $600,000. The grant is intended to support BrainStorm's clinical development for its innovative stem cell therapy candidate NurOwn(TM).

BrainStorm Issues Annual Letter to Shareholders
Business Wire - Tue Feb 04, 7:00AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today issued a Letter to Shareholders from its President, Mr. Chaim Lebovits, summarizing the company's major developments in 2013.

BrainStorm Receives US Notice of Allowance for its Key Stem Cell Technology Patent
Business Wire - Mon Feb 03, 7:00AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from the U.S. Patent Office for its "Mesenchymal Stem Cells for the Treatment of CNS Diseases" (serial number 12/994,761) patent application.

BrainStorm Signs Definitive Agreement with Mayo Clinic for ALS Clinical Trial and NurOwn Manufacturing
Business Wire - Wed Jan 29, 7:00AM CST
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Mayo Clinic in Rochester, Minnesota to conduct its Phase II clinical trial of NurOwn(TM) in amyotrophic lateral sclerosis (ALS), pending FDA approval. In addition, Mayo's Human Cell Therapy Laboratory will manufacture the NurOwn cells for their clinical trial participants. The other two sites slated for the multi-center trial are the University of Massachusetts Memorial Hospital and Massachusetts General Hospital.

BrainStorm Hosting a Conference Call with Clinical Trial Advisors in Israel, US and Brazil to Update Shareholders on Current Developments
Business Wire - Wed Jan 15, 7:00AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Thursday, January 30, 2014 at 8:45 a.m. Eastern Standard Time (EST), 15:45 Israel Standard Time (IST).

BrainStorm Cell Therapeutics awarded US Patent Office's Notice of Allowance for stem cell technology
M2 - Tue Jan 14, 4:51AM CST
Biotechnology company BrainStorm Cell Therapeutics (OTC BB:BCLI) reported on Monday the receipt of a Notice of Allowance for its 'Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases'.

BrainStorm Receives United States Patent Office Notice of Allowance for Its Stem Cell Technology
Business Wire - Mon Jan 13, 8:42AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from the U.S. Patent Office for its "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases" (serial number 11/727,583) patent application.

BrainStorm Receives Notice of Allowance to Grant European Patent Covering its Stem Cells for the Treatment of CNS Diseases
Business Wire - Wed Jan 08, 8:00AM CST
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received notification from the European Patent Office (EPO) of its intention to grant the company's patent application No. EP06766101.7 entitled "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases."

Significant Clinical Findings on ALS Patient Treated with BrainStorm's NurOwn Featured in "Muscle and Nerve"
Business Wire - Mon Jan 06, 7:30AM CST
BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced the upcoming publication of a case report on an individual patient treated with the company's NurOwn(TM) cell therapy in "Muscle & Nerve" (John Wiley & Sons). The report, which looked at one patient diagnosed with both Myasthenia Gravis (MG) and Amyotrophic Lateral Sclerosis (ALS) showed significant improvements in both cognitive and motor function following initial and repeat treatments with NurOwn.

2013 Report on the International Stem Cells Market - Includes Forecast to 2018
M2 - Wed Dec 18, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/732xpm/stem_cells_market) has announced the addition of the "2013 Report on the International Stem Cells Market - Includes Forecast to 2018" report to their offering. "2013 Report on the International Stem Cells Market - Includes Forecast to 2018", highlights the market shares of key players in 2011. The company profiles for some of the key players, namely Advanced Cell Technology Inc., STEMCELL Technologies Inc., Cellular Engineering Technologies Inc., BioTime Inc., Aastrom Biosciences Inc. and California Stem Cell Inc. in terms of company overview, financial overview, business strategies, recent developments and product portfolio is also covered. The global stem cells market is categorized into the following segments: - Stem Cells Market by Products - Adult Stem Cells - Hematopoietic Stem Cells - Mesenchymal Stem Cells - Neuronal Stem Cells - Dental Stem Cells - Umbilical Cord Stem Cells - Human Embryonic Stem Cells - Induced Pluripotent Stem Cells - Natural Rosette Cells - Very Small Embryonic Like Stem Cells - Stem Cells Market by Technology - Cell Acquisition - Bone Marrow Harvest - Apheresis - Umbilical Blood Cord - Cell Production - Therapeutic Cloning - In Vitro Fertilization - Isolation - Cell Culture - Cryopreservation - Expansion and Sub-Culture - Stem Cells Market by Applications - Regenerative Medicine - Neurological Disorders - Orthopedics - Cancer - Hematological disorders - Cardiovascular diseases Stem Cells Market by Geography - North America - Europe - Asia - Rest of the World (RoW) Key Topics Covered: 1 Preface 1.1 Report Description 1.2 Research Methodology 2 Executive Summary 3 Market Overview 3.1 Market Trends and Future Outlook 3.2 Market Dynamics 3.3 Market Attractiveness 4 Global Stem Cells Market, By Products 4.1 Market Segmentation: Global Stem Cells Market, By Products 4.2 Overview 4.3 Adult Stem Cells Market, 2010 - 2018 (USD Billion) 4.4 Human Embryonic Stem Cells Market, 2010 - 2018 (USD Billion) 4.5 Induced Pluripotent Stem Cells Market, 2010 - 2018 (USD Billion) 4.6 Rat Neural Stem Cells Market, 2010 - 2018 (USD Billion) 4.7 Very Small Embryonic-Like Stem Cells Market, 2010 - 2018 (USD Billion) 5 Global Stem Cells Market, By Technology 6 Global Stem Cells Market, By Application 7 Global Stem Cells Market, By Geography 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Advanced Cell Technology - Angel Biotechnology - Bioheart - Biotime Inc. - Brainstorm Cell Therapeutics - California Stem Cell Inc. - Celgene Corporation Inc. - Cellartis AB - Cellular Engineering Technologies - Cytori Therapeutics Inc. - Osiris Therapeutics - Stemcelltechnologies Inc. For more information visit http://www.researchandmarkets.com/research/73...lls_market

Global Stem Cell Market Report 2013
M2 - Tue Dec 17, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/qsfq7f/stem_cell_markets) has announced the addition of the "Global Stem Cell Market Report 2013" report to their offering. Traditionally, stem cells have been classified as either embryonic, adult (tissue-specific or cord blood) stem cells. However, recent understanding of stem cell biology may provide new approaches for the treatment of a number of diseases as well as tissue/organ injuries, including cardiovascular disease, neurological disease, musculoskeletal disease, diabetes and hematopoietic disorders. Stem cell fate is determined by both intrinsic regulators and the extra-cellular environment (niche), and their expansion and differentiation ex vivo are generally controlled by growing them in a specific configuration (monolayer or three-dimensional culture). This process, which is vital to enable stem cells to be used for therapeutic purposes, is called differentiation. Differentiation is a process involving unspecialized cells progressing to become specialized cells with restricted developmental potential. "Global Stem Cell Market Report 2013", describes the specific market segments of the medical research space using stem cells for research and development (R&D) purposes. This study reviews all of the generally accepted analytical methods that are currently in use today for preparing and using stem cells. Key Topics Covered: 1. Overview 2. Biology of Stem Cells 3. Stem Cell Therapy 4. Market Analysis of the Stem Cell Space 5. Strategic Roadmap to Cell Therapy Industry 6. Funding for Regenerative Medicine Research 7. Current Stem Cell Research 8. Company Profiles Companies Mentioned: - Athersys, Inc - Brainstorm Cell Therapeutics, Inc - CryoLife, Inc - Epistem PLC - Forticell Bioscience, Inc - Glycosan Biosystems, Inc - Humacyte, Inc - International Stem Cell Corporation - Japan Tissue Engineering Co., Ltd - LifebankUSA - Miltenyi Biotec - Novocell, Inc - Osiris Therapeutics, Inc - Pluristem Therapeutics, Inc - ReNeuron Group Plc - Stempeutics Research Private Limited - Tengion, Inc - VistaGen Therapeutics, Inc - ZenBio, Inc For more information visit http://www.researchandmarkets.com/research/qs...ll_markets

BrainStorm Cell Therapeutics Inc wins USD800,000 OCS grant in Israel
M2 - Thu Dec 12, 3:29AM CST
Adult stem cell company BrainStorm Cell Therapeutics Inc (OTC BB:BCLI) reported on Wednesday the receipt of a USD800,000 non-dilutive grant from Israel's Office of the Chief Scientist (OCS) for the year 2014.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chipotle's Thanksgiving BOGO Tests Loyalty Muscle Again

Updated Category News Views 52

Thanksgiving Eve is a peculiar little battlefield for restaurant chains: everybody wants the reunion crowd, nobody wants to give away the register. Chipotle is stepping back into it on Wednesday, November 25, with its Back Home BOGO for Rewards members from 5 to 9 p.m. local time at participating U.S. restaurants. Buy an entrée in person, scan the Rewards account, and...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 107

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 46

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 34

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
Pompeii Fountain Tests the Value of Concrete Durability

Updated Category News Views 96

Nearly 2,000 nozzles throwing water around a public attraction is a fine way to expose every weak seam in a concrete job. The Fontana Danzante in Pompei, completed in late 2025, is not some quiet decorative basin. It is described as Italy's largest fountain, a nearly 200-meter installation near the Pompeii Archaeological Park that continuously stores, circulates and...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 12

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 61

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 40

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 50

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 73

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading

Top 5 Most Recently Viewed Articles

Priority Income Fund Sets Attractive Cash Distribution Rates

Updated Category News Views 189

Priority Income Fund Announces Attractive Distribution Rates Priority Income Fund, Inc. has recently declared exciting news for its investors. The Fund's Board of Directors has announced monthly cash distributions distinguished into "base" and "bonus" shareholder distributions for the forthcoming months. These distributions are set for September, October, and November of...

Continue Reading
Yum China Achieves Extraordinary Sustainability Milestone Again

Updated Category News Views 137

Yum China’s Leadership in Sustainability Recognized Globally Yum China Holdings, Inc. (NYSE: YUMC) has made significant strides this year by achieving the remarkable distinction of being ranked number one in the global Restaurant & Leisure Facilities Industry according to the S&P Global 2024 Corporate Sustainability Assessment (CSA). This achievement marks the fifth...

Continue Reading
Lumibird's 2024 Annual Results: Growth and Challenges

Updated Category News Views 397

Lumibird's Annual Results: A Year of Contrasts In the latest reporting window, Lumibird, a leader in laser technology, delivered its annual results for the year. The company achieved an EBITDA margin of 15.9%, driven primarily by the Medical division, which performed notably well. By contrast, the Photonics division faced challenges, contributing to an overall mixed...

Continue Reading
Keysight Technologies Introduces Enhanced Testing for Defense Software

Updated Category News Views 138

Keysight Technologies Boosts Software Testing with Eggplant Keysight Technologies, Inc. (NYSE: KEYS) recently revealed that its Eggplant Test is now available in the Iron Bank marketplace. This platform provides a crucial secure repository for advanced applications, specifically designed for defense organizations. With Eggplant Test deployed, businesses can ensure their...

Continue Reading
Exploring the Impact of Blue Light Cystoscopy on Bladder Cancer

Updated Category News Views 324

New Insights from the BRAVO Study on Bladder Cancer Management Photocure ASA, recognized as the Bladder Cancer Company, has recently unveiled compelling findings from the BRAVO study, which assesses the effectiveness of blue light cystoscopy (BLC) in the treatment of bladder cancer. This innovative approach outlines how BLC enhances the detection of non-muscle-invasive...

Continue Reading